Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89


Depletion of PD-1-positive cells ameliorates autoimmune disease.

Zhao P, Wang P, Dong S, Zhou Z, Cao Y, Yagita H, He X, Zheng SG, Fisher SJ, Fujinami RS, Chen M.

Nat Biomed Eng. 2019 Apr;3(4):292-305. doi: 10.1038/s41551-019-0360-0. Epub 2019 Mar 4.


Nonoverlapping roles of PD-1 and FoxP3 in maintaining immune tolerance in a novel autoimmune pancreatitis mouse model.

Zhang B, Chikuma S, Hori S, Fagarasan S, Honjo T.

Proc Natl Acad Sci U S A. 2016 Jul 26;113(30):8490-5. doi: 10.1073/pnas.1608873113. Epub 2016 Jul 7.


Poxvirus-Based Active Immunotherapy with PD-1 and LAG-3 Dual Immune Checkpoint Inhibition Overcomes Compensatory Immune Regulation, Yielding Complete Tumor Regression in Mice.

Foy SP, Sennino B, dela Cruz T, Cote JJ, Gordon EJ, Kemp F, Xavier V, Franzusoff A, Rountree RB, Mandl SJ.

PLoS One. 2016 Feb 24;11(2):e0150084. doi: 10.1371/journal.pone.0150084. eCollection 2016.


CD8+ T cells undergo activation and programmed death-1 repression in the liver of aged Ae2a,b-/- mice favoring autoimmune cholangitis.

Concepcion AR, Salas JT, Sáez E, Sarvide S, Ferrer A, Portu A, Uriarte I, Hervás-Stubbs S, Oude Elferink RP, Prieto J, Medina JF.

Oncotarget. 2015 Oct 6;6(30):28588-606. doi: 10.18632/oncotarget.5665.


PD-L1 checkpoint inhibition and anti-CTLA-4 whole tumor cell vaccination counter adaptive immune resistance: A mouse neuroblastoma model that mimics human disease.

Srinivasan P, Wu X, Basu M, Rossi C, Sandler AD.

PLoS Med. 2018 Jan 29;15(1):e1002497. doi: 10.1371/journal.pmed.1002497. eCollection 2018 Jan.


Elimination of tumor by CD47/PD-L1 dual-targeting fusion protein that engages innate and adaptive immune responses.

Liu B, Guo H, Xu J, Qin T, Guo Q, Gu N, Zhang D, Qian W, Dai J, Hou S, Wang H, Guo Y.

MAbs. 2018 Feb/Mar;10(2):315-324. doi: 10.1080/19420862.2017.1409319. Epub 2017 Dec 20.


Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs.

Lu L, Xu X, Zhang B, Zhang R, Ji H, Wang X.

J Transl Med. 2014 Feb 7;12:36. doi: 10.1186/1479-5876-12-36.


A missing PD-L1/PD-1 coinhibition regulates diabetes induction by preproinsulin-specific CD8 T-cells in an epitope-specific manner.

Schuster C, Brosi H, Stifter K, Boehm BO, Schirmbeck R.

PLoS One. 2013 Aug 19;8(8):e71746. doi: 10.1371/journal.pone.0071746. eCollection 2013.


Curcumin ameliorates autoimmune diabetes. Evidence in accelerated murine models of type 1 diabetes.

Castro CN, Barcala Tabarrozzi AE, Winnewisser J, Gimeno ML, Antunica Noguerol M, Liberman AC, Paz DA, Dewey RA, Perone MJ.

Clin Exp Immunol. 2014 Jul;177(1):149-60. doi: 10.1111/cei.12322.


PD-1 ligands expressed on myeloid-derived APC in the CNS regulate T-cell responses in EAE.

Schreiner B, Bailey SL, Shin T, Chen L, Miller SD.

Eur J Immunol. 2008 Oct;38(10):2706-17. doi: 10.1002/eji.200838137.


Bifunctional PD-1 × αCD3 × αCD33 fusion protein reverses adaptive immune escape in acute myeloid leukemia.

Herrmann M, Krupka C, Deiser K, Brauchle B, Marcinek A, Ogrinc Wagner A, Rataj F, Mocikat R, Metzeler KH, Spiekermann K, Kobold S, Fenn NC, Hopfner KP, Subklewe M.

Blood. 2018 Dec 6;132(23):2484-2494. doi: 10.1182/blood-2018-05-849802. Epub 2018 Oct 1.


Programmed cell death 1 inhibits inflammatory helper T-cell development through controlling the innate immune response.

Rui Y, Honjo T, Chikuma S.

Proc Natl Acad Sci U S A. 2013 Oct 1;110(40):16073-8. doi: 10.1073/pnas.1315828110. Epub 2013 Sep 16.


Forced expression of programmed death-1 gene on T cell decreased the incidence of type 1 diabetes.

Won TJ, Jung YJ, Kwon SJ, Lee YJ, Lee DI, Min H, Park ES, Joo SS, Hwang KW.

Arch Pharm Res. 2010 Nov;33(11):1825-33. doi: 10.1007/s12272-010-1115-3. Epub 2010 Nov 30.


Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses.

Liu J, Yuan Y, Chen W, Putra J, Suriawinata AA, Schenk AD, Miller HE, Guleria I, Barth RJ, Huang YH, Wang L.

Proc Natl Acad Sci U S A. 2015 May 26;112(21):6682-7. doi: 10.1073/pnas.1420370112. Epub 2015 May 11.


The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.

Mahoney KM, Freeman GJ, McDermott DF.

Clin Ther. 2015 Apr 1;37(4):764-82. doi: 10.1016/j.clinthera.2015.02.018. Epub 2015 Mar 29. Review.


Nafamostat mesilate, a serine protease inhibitor, suppresses interferon-gamma-induced up-regulation of programmed cell death ligand 1 in human cancer cells.

Homma S, Hayashi K, Yoshida K, Sagawa Y, Kamata Y, Ito M.

Int Immunopharmacol. 2018 Jan;54:39-45. doi: 10.1016/j.intimp.2017.10.016. Epub 2017 Oct 28.


Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.

Wu SP, Liao RQ, Tu HY, Wang WJ, Dong ZY, Huang SM, Guo WB, Gou LY, Sun HW, Zhang Q, Xie Z, Yan LX, Su J, Yang JJ, Zhong WZ, Zhang XC, Wu YL.

J Thorac Oncol. 2018 Apr;13(4):521-532. doi: 10.1016/j.jtho.2017.11.132. Epub 2017 Dec 18.


Anti-IgD antibody attenuates collagen-induced arthritis by selectively depleting mature B-cells and promoting immune tolerance.

Nguyen TG, Little CB, Yenson VM, Jackson CJ, McCracken SA, Warning J, Stevens V, Gallery EG, Morris JM.

J Autoimmun. 2010 Aug;35(1):86-97. doi: 10.1016/j.jaut.2010.03.003. Epub 2010 Apr 24.


Regulation of effector function of CNS autoreactive CD4 T cells through inhibitory receptors and IL-7Rα.

Nuro-Gyina PK, Rieser EL, Granitto MC, Pei W, Liu Y, Lee PW, Aqel S, Zhang J, Lovett-Racke AE, Racke MK, Yang Y.

J Neuroinflammation. 2016 Dec 3;13(1):302.


Myeloid cells are required for PD-1/PD-L1 checkpoint activation and the establishment of an immunosuppressive environment in pancreatic cancer.

Zhang Y, Velez-Delgado A, Mathew E, Li D, Mendez FM, Flannagan K, Rhim AD, Simeone DM, Beatty GL, Pasca di Magliano M.

Gut. 2017 Jan;66(1):124-136. doi: 10.1136/gutjnl-2016-312078. Epub 2016 Jul 8.

Supplemental Content

Support Center